Evidence map›Paper›PMID 37031461›Full record

ArticleCancer medicine2023

A modeling study to estimate prostate cancer-specific mortality on active surveillance for men with favorable intermediate-risk prostate cancer: Results from the SEARCH cohort.

Paige K Kuhlmann, Taofik Oyekunle, Zachary Klaassen, Christopher L Amling, William J Aronson, Matthew R Cooperberg, Christopher J Kane, Martha K Terris, Stephen J Freedland

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 1 country.

Paige K KuhlmannDivision of Urology, Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, California, USA.ORCID 0000-0001-9547-6797
Taofik OyekunleSection of Urology, Durham VA Medical Center, Durham, North Carolina, USA.
Zachary KlaassenDepartment of Surgery, Section of Urology, Augusta University - Medical College of Georgia, Augusta, Georgia, USA.
Christopher L AmlingDepartment of Urology, Oregon Health and Science University School of Medicine, Portland, Oregon, USA.
William J AronsonDepartment of Urology, University of California, Los Angeles, California, USA.
Matthew R CooperbergDepartment of Urology, University of California, San Francisco, California, USA.
Christopher J KaneDepartment of Urology, University of California, San Diego, California, USA.
Martha K TerrisDepartment of Surgery, Section of Urology, Augusta University - Medical College of Georgia, Augusta, Georgia, USA.
Stephen J FreedlandDivision of Urology, Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, California, USA.ORCID 0000-0002-8104-6419
Augusta University · USCedars-Sinai Medical Center · USDuke University · USOregon Health & Science University · USUniversity of California, San Francisco · USUniversity of California System · USWadsworth Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeLimited data exist to help surgeons decide between active surveillance (AS) versus treatment for men with favorable intermediate risk (FIR) prostate cancer. To estimate the theoretical excess risk of prostate cancer-specific mortality (PCSM) with AS versus radical prostatectomy (RP), we determined the risk of PCSM in FIR men undergoing RP and modeled the PCSM risk for AS using a range of increased PSCM scenarios ranging from 1.25x to 2x higher relative to RP. MATERIALS AND

methodsWe retrospectively reviewed data from men undergoing RP from 1988 to 2017 at 8 Veterans Affairs hospitals within the SEARCH cohort. Men with FIR PC were identified using the NCCN risk criteria. Risk of PCSM at 5, 10, and 15 years after RP was estimated. Using these estimates, PCSM was then modeled for AS using a range of increased risk of PCSM relative to RP ranging from 1.25x to 2x higher.

resultsFor the 920 FIR men identified, 5-, 10-, and 15-year survival estimates for PCSM after RP were 99.9%, 99.0%, and 97.8%, respectively. If the risk of PCSM on AS were 1.25-2x greater than RP, there would be 0.54%-2.17% excess risk of PCSM at 15 years.

conclusionsThe risk of death for FIR after RP is very low. Assuming even modestly increased PCSM with AS versus RP, the excess risk of death for AS in FIR is low even up to 15 years. These data support the consideration of AS as a relatively safe alternative to RP in FIR men, though prospective randomized trials are needed to validate these findings.

Indexed as

Prostatic NeoplasmsWatchful WaitingHumansMaleProspective StudiesProstateProstatectomyRetrospective Studiesactive surveillancefavorable intermediate riskprostate cancerprostate cancer-specific mortality

Identifiers

PMID37031461
PMCPMC10225172
OpenAlexW4362724436

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.